AKARI Therapeutics Company

Akari is developing inhibitors of acute and chronic inflammation, specifically the complement and leukotriene systems, to treat rare and orphan diseases with unmet need.


Connections from

Investor Type: N/A
Industry: Stem Cell Exhaustion
Number Of Exists: N/A
Funding Status: IPO
Technology: Scientifically-Validated Lifestyle Recommendation
Employee Number: 11-50
Headquarters: United States
Investment Stage: N/A
Founded Date: 2005